<DOC>
	<DOCNO>NCT00296244</DOCNO>
	<brief_summary>The purpose study determine whether steroid-related complication avoid use steroid-free immuno-suppressive drug regimen liver transplantation .</brief_summary>
	<brief_title>Steroid Free Immunosuppression Liver Transplantation</brief_title>
	<detailed_description>Steroids remain standard part post-transplant immunosuppression , prevention treatment rejection . However , steroid show cause long-term adverse effect , : susceptibility infection , obesity , hypertension , hyperlipidemia , diabetes , osteopenia , cataracts growth retardation child . They also implicate accelerate Hepatitis C virus ( HCV ) re-infection post-liver transplantation . Several study show early steroid reduction withdrawal could do safely alleviate many steroid-related adverse effect liver transplantation ( OLT ) . This prospective control randomized trial adult patient undergo primary OLT Thomas Jefferson University Hospital ( TJUH ) . Forty consecutive OLT recipient shall randomize two group . - Control group- immuno-suppressive drug regimen consist basiliximab ( Simulect ) , tacrolimus ( Prograf ) , Mycophenolic acid ( Myfortic ) , steroid - Study group- immuno-suppressive drug regimen consist basiliximab , tacrolimus , Mycophenolic acid ( Myfortic ) without steroid Basiliximab give 20 mg IV bolus intra-operatively 4th day transplantation . Tacrolimus shall administer dose 0.15mg/ kg/ day mouth naso-gastric tube ( NGT ) , start earlier 24 transplant within 48 hrs reperfusion . The dose shall adjust achieve trough level 10-15 ng/ml first 30 day transplantation lower 5-10 ng/ml , thereafter . Patients randomize control group shall administer methylprednisolone ( Solumedrol ) 1000 mg IV anhepatic phase . Methylprednisolone continue accord follow taper schedule : 50 mg IV every 6 hr day 1 ; 40 mg IV every 6hrs day 2 ; 30 mg IV every 6 hr day 3 ; 20 mg IV every 6 hr day 4 ; 20 mg IV every 12 hr day 5 ; Prednisone 20 mg mouth NGT day 6 . Prednisone shall taper slowly start 1 month post-OLT wean completely 6 month post-OLT . Enteric-coated mycophenolic acid EC-MPA ( Myfortic ) add regimen , particularly patient renal impairment neuro-toxicity minimize dose effect tacrolimus . It start 720 mg P.O . 2x/ day immediately post-transplant shall give period 3 month . Primary end point study 6 month post-transplant include : graft patient survival rate , incidence acute rejection therapy employ treat rejection . Secondary end point include : adverse effect steroid , particularly , diabetes , obesity , hyperlipidemia , hypertension ; incidence severity HCV recurrence , incidence infectious complication . Blood sample HCV recipient shall collect day surgery , 2 week , 1 month , 3 month , 6 month post-OLT per TJUH Liver Transplant Protocol . Sera shall store -80C use quantitative HCV RNA level quantitative polymerase chain reaction . Protocol liver biopsy shall perform time surgery , 7-21 day post-OLT approximately 3 month transplantation clinically indicate elevate liver function test result . Acute rejection shall treat initially increase tacrolimus dose achieve level 15-20 ng/ml 48 hr . If liver function test result show improvement 3rd day increase tacrolimus dose , biopsy perform . Only biopsy proven rejection shall treat accord follow protocol . Mild moderate rejection shall treat study group methylprednisolone 1 gm IV tapering dos steroid describe . Steroids shall discontinue completion taper . In control group , methylprednisolone 1 gm IV shall follow taper dos prednisone 20 mg daily , shall progressively reduce accordingly . The protocol shall also include repeat biopsy improvement liver function test end steroid taper . Severe rejection steroid resistant rejection shall treat OKT3 5mg IV/ day 5-10 day pre-medication . Recipients HCV recurrence shall treat accord TJUH Liver Transplant protocol follow . Abnormal liver function test evaluate hepatic image exclude anatomic abnormality . If none , liver biopsy do . If liver biopsy show &gt; grade 4 ( inflammation mild ) &gt; stage 1 ( fibrosis ) , consider antiviral treatment consist Peg-Interferon alpha-2a 180mcg subcutaneously weekly two week . If patient tolerates peg-interferon hematologic neuro-psychiatric standpoint , continue peg-interferon , add ribavirin . Refer protocol dose . Total duration therapy 48 week . Follow period primary analysis six ( 6 ) month .</detailed_description>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female patient 18 72 year age Male female patient primary cadaveric liver transplant recipient Cold ischemia time must &lt; 20 hour Females capable become pregnant must negative pregnancy test baseline require practice approve method birth control duration study period three month follow discontinuation study medication Patient give write informed consent participate study Patients meet follow criterion baseline exclude study participation Patients previously receive organ transplant Patients recipient multiple organ transplant Women childbearing potential use contraception method ( ) specify study , well woman breastfeed Known sensitivity Simulect class Simulect Patients severe medical condition ( ) view investigator prohibit participation study Use investigational agent last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>steroid-free immunosuppression</keyword>
	<keyword>liver transplantation</keyword>
</DOC>